The New Strategy for Pharmacological Treatment in People With Schizophrenia

Inje University

Status and phase: Unknown; Phase 4

Conditions: Schizophrenia

Treatments: Drug: Rispridoen and Aripiprazole; Drug: Risperidne; Drug: Abilify

Study type: Interventional

Funder types: Other

Identifiers

NCT00352339

Aripiprazole study 2006

Details and patient eligibility

About

Switching from Risperidone to Aripiprazole in early stage of pharmacotherapy will demonstrate the same efficacy as compared to risperidone continuation treatment in the treatment of schizophrenia.

Full description

It has been thought that D2 Blocking agent is necessary in acute as well as maintenance phase of pharmacological treatment of patients with schizophrenia. However, this classical strategy produces long term adverse events of drug such as TD, osteoporosis and some metabolic syndrome. To overcome these adverse events, new strategy for pharmacological treatment is needed.

Enrollment: 90 estimated patients

Sex: All

Ages: 18 to 45 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Schizophrenia, DSM-IV
• Acute phase

Exclusion criteria

• Refractory Schizophrenia
• Substance Abuse
• High risk for suicide

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

90 participants in 3 patient groups

Aripiprazole

Experimental group

Description:

switching group (from risperidone to aripiprazole)

Treatment:

Drug: Rispridoen and Aripiprazole

Risperidone

Active Comparator group

Description:

Start with risperidone and keep it through the end of study

Treatment:

Drug: Risperidne

Abilify

Active Comparator group

Description:

Start with aripiprazole and keep it through the end of study

Treatment:

Drug: Abilify